Free Trial
NYSE:MTNB

Matinas Biopharma (MTNB) Stock Price, News & Analysis

Matinas Biopharma logo
$1.03 0.00 (0.00%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$1.01 -0.02 (-1.46%)
As of 07/11/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Matinas Biopharma Stock (NYSE:MTNB)

Key Stats

Today's Range
$1.00
$1.04
50-Day Range
$0.63
$1.04
52-Week Range
$0.47
$9.60
Volume
72,716 shs
Average Volume
241,044 shs
Market Capitalization
$5.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Receive MTNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Matinas Biopharma and its competitors with MarketBeat's FREE daily newsletter.

MTNB Stock News Headlines

MTNB Matinas BioPharma Holdings, Inc. - Seeking Alpha
Matinas BioPharma Holdings, Inc. (MTNB) - Yahoo Finance
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
Matinas BioPharma files to sell 16.9M shares of common stock for holders
Matinas BioPharma appoints Murphy, Neugeboren to board of directors
See More Headlines

MTNB Stock Analysis - Frequently Asked Questions

Matinas Biopharma's stock was trading at $0.51 at the beginning of the year. Since then, MTNB stock has increased by 102.0% and is now trading at $1.03.

Matinas Biopharma Holdings, Inc. (NYSE:MTNB) posted its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.02) EPS for the quarter, hitting the consensus estimate of ($0.02).

Shares of MTNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Matinas Biopharma investors own include AcelRx Pharmaceuticals (ACRX), DURECT (DRRX), Kosmos Energy (KOS), Strongbridge Biopharma (SBBP), Selecta Biosciences (SELB), Acasti Pharma (ACST) and Abeona Therapeutics (ABEO).

Company Calendar

Last Earnings
8/14/2024
Today
7/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:MTNB
Previous Symbol
NYSE:MTNB
CIK
1582554
Web
N/A
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($3.86)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$22.94 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-123.06%
Return on Assets
-94.28%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.53
Quick Ratio
5.53

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.43 per share
Price / Book
0.23

Miscellaneous

Outstanding Shares
5,087,000
Free Float
4,599,000
Market Cap
$5.24 million
Optionable
N/A
Beta
1.31
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NYSE:MTNB) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners